Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus temozolomide versus temozolomide for first recurrent primary glioblastoma in adults
ChiCTR1900020646Phase 4Recruiting
- Sponsor
- Beijing Sanbo Brain Hospital
- Start
- Feb 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in glioblastoma (GBM) comparing Apatinib combined with temozolomide with Temozolomide control (2 arms). Primary endpoint: 6-month progression-free survival rate. Started Feb 2019; status: recruiting.
02
Drugs
Rivoceranibtemozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ChiCTR1900020646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900020646.